MIRA Pharmaceuticals' Oral Mira-55 Surpasses Morphine in Pain Management

MIRA Pharmaceuticals recently announced promising preclinical results for its oral medication, Mira-55, which outperformed injected morphine in normalizing pain and reducing inflammation. This development supports the company's strategy to target the $70 billion non-opioid pain market.

The study measured pain sensitivity using Von Frey Filament testing and inflammation through paw-edema volume. Results demonstrated that oral Mira-55 not only restored pain thresholds to baseline levels but also significantly lessened inflammation, unlike morphine, which offered partial relief.

MIRA Pharmaceuticals aims to refine chronic inflammatory pain treatment through Mira-55's CB2 receptor-mediated anti-inflammatory properties, presenting a safer alternative to traditional opioids and NSAIDs.

With its dual benefits as an analgesic and anti-inflammatory, Mira-55 shows promise as a next-generation therapeutic solution without the sedative or addictive risks associated with opioids, advancing the company's clinical pipeline.